Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GeneTx Biotherapeutics LLC

http://

Latest From GeneTx Biotherapeutics LLC

Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.

BioPharmaceutical Neurology

Finance Watch: Joe Jimenez Ventures Into Start-Up World Via Aditum

Former Novartis CEO Jimenez co-founded Aditum with former NIBR president Mark Fishman; they raised $133m and are launching Tempero Bio. Also, Atea, Galecto and SQZ went public along with one more health care SPAC, Royalty Pharma upped its Vertex royalty revenues and Mirati’s FOPO raised $926.3m.

Financing Deals

Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership

Deals Business Strategies

Big Companies are from Mars, Small Companies from Venus

A review of the Phoenix '97 CEO conference shows there's a long way to go in bridging the communication gap between large and small companies.

Medical Device Strategy
See All

Company Information

  • Industry
  • Biotechnology
UsernamePublicRestriction

Register